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Available online xxxxEctopic pregnancies complicate 1–2 pregnancies and are a leading cause ofmaternal death. An effective oral drug
therapy that replaces surgerymightmake its treatment safer, cheaper, simpler and thereforemorewidely acces-
sible. The only currentmedical treatment offered to women is intramuscular methotrexate, but this only reliably
resolves smaller ectopic pregnancies. As such, many ectopic pregnancies require surgical excision. We show that
vinorelbine, an orally available chemotherapeutic agent, potently induced placental cell death but did not harm
fertility inmice. Vinorelbinewas 100–1000 timesmorepotent thanmethotrexate in inducing placental cell death
in vitro, and more potent than combination methotrexate and geﬁtinib (another proposed treatment for ectopic
pregnancy being evaluated in phase III trials). Mechanistically, it caused microtubule condensation, blocked mi-
tosis and activated the apoptosis cascade in placental cells. Vinorelbine was more efﬁcacious than methotrexate
± geﬁtinib in reducing the volume of placental cell tumors xenografted subcutaneously in SCID mice. Mice ex-
posed to vinorelbine and allowed to breed, following a four week washout period, displayed normal fertility,
however long-term fertility was not assessed. Human Fallopian tubes treated with vinorelbine did not exhibit
up-regulation of apoptosis molecules. Our ﬁndings show that placental cells appear sensitive to vinorelbine
and it has potential as a tablet-only approach to treat ectopic pregnancy.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Ectopic pregnancy
Vinorelbine
Methotrexate
Placenta
Treatment1. Introduction
Ectopic pregnancies arise when a conceptus implants outside the
uterine cavity, with over 98% implanting in the Fallopian tube (Bouyer
et al., 2002). They are life-threatening as they can erode throughmater-
nal vessels and cause fatal bleeding (Knight et al., 2016) and are one of
the main causes of maternal death during the ﬁrst trimester. They are
also common, complicating 1–2% of all pregnancies with around
100,000 cases diagnosed each year in the United States alone (Centre
for Disease Control and Prevention, 1995).
Many are treated surgically (Jurkovic and Wilkinson, 2011) where
often, the entire Fallopian tube is removed together with the ectopic
pregnancy. A simple and highly efﬁcacious medical option could makeroup, Department of Obstetrics
of Melbourne, 163 Studley Rd,
. This is an open access article under
orelbine Potently Induces Pla
, https://doi.org/10.1016/j.ebithe treatment of ectopic pregnancy safer (avoiding the risks of surgery),
simpler (requiring less highly trained staff) and cheaper. The further im-
plications are that the treatment could become more accessible in re-
source poor settings where surgery is either difﬁcult to access, or not
available.
There is one medical treatment offered clinically instead of surgery,
intramuscular methotrexate (RCOG, 2016; The ACOG Task Force,
2008). However, methotrexate is only efﬁcacious for smaller ectopic
pregnancies that fulﬁll strict clinical criteria, and its rates of failure are
too high for larger ectopic pregnancies (which will then often require
salvage surgery) (RCOG, 2016). Furthermore, it often takes approxi-
mately one month for the ectopic pregnancy to resolve following
methotrexate management (Skubisz et al., 2013) and, owing to its
limited effectiveness, is less cost effective than laparoscopic (surgical)
excision(Mol et al., 2008). Consequently, many ectopic pregnancies
are surgically excised (Jurkovic and Wilkinson, 2011).
We previously identiﬁed the possibility that adding geﬁtinib tablets
(an epidermal growth factor inhibitor that adversely affects placental
signaling to cause apoptosis) to the intramuscular methotrexate mightthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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are currently evaluating this in a phase III randomized trial (EudraCT
No: 2015-005013-76). Aside from this, there appears to be a distinct
lack of other medical alternatives to treat ectopic pregnancy, either
touted at the preclinical stage, or in trials (Tong et al., 2015).
Vinorelbine is a semi-synthetic vinca-alkaloid derived from the
Madagascar periwinkle (Noble, 1990). First manufactured in 1979, it is
considered a well tolerated chemotherapeutic. Vinorelbine induces cy-
totoxicity by binding to tubulin, which disrupts mitotic spindle forma-
tion and results in arrest of the cell cycle at the metaphase to
anaphase transition. This ultimately leads to apoptosis of mitotic cells
(Wang et al., 1999). Vinorelbine is highly selective to mitotic rather
than axonal microtubules, which means it preferentially targets divid-
ing and highly proliferative cells (Binet et al., 1989; Paintrand and
Pignot, 1983). It is currently approved to treat non-small cell lung can-
cer, Hodgkin's lymphoma, breast and ovarian cancers (Gregory and
Smith, 2000). Given the placenta is highly proliferative during the ﬁrst
trimester but the Fallopian tube is not, it is plausible that vinorelbine
could be efﬁcacious in resolving an ectopic pregnancy whilst minimally
affecting the surrounding tube.
Importantly, there is an oral formulation of vinorelbine. Thus, if
found to be highly effective the potential exists that a tablet-only treat-
ment could be used in place of surgery to treat most ectopic pregnan-
cies. Here, we set out to investigate the potential of vinorelbine to
treat ectopic pregnancy. We compared the efﬁcacy of vinorelbine to
methotrexate, and to combination methotrexate and geﬁtinib.
2. Materials and Methods
2.1. Cell Culture and Treatment
Trophoblast cell lines, JEG3 and HTR 8/SVneo were cultured at 37 °C
in 5% CO2 humidiﬁed atmosphere in DMEM (Life Technologies,
California, USA) or RPMI (Life Technologies) medium supplemented
with 10% fetal bovine serum (FBS). For various experiments, cells
were treated with the following drugs at the dose ranges of 0.01–100
μM vinorelbine (Sigma, Croydon, UK), vincristine (Sigma), etoposide
(Sigma), gemcitabine (Sigma), 5-ﬂuorouracil (Sigma), cisplatin
(Sigma), herceptin (Roche, Basel, Switzerland), Actinomysin D
(Sigma) or vehicle control. For some experiments we also treated
drugs with geﬁtinib (Sigma) at 8 μl. All experiments were repeated at
least three times in triplicate.
2.2. In Vitro Cell Viability and Proliferation
Cell viability was measured via MTS assay 48 h after treatment, as
per manufacture's instructions (Promega, Wisconsin, USA) optical den-
sity determined using BioRad X-Mark microplate spectrophotometer
(BioRad, California, USA).
Evaluation of cellular proliferation was measured using the real-
time monitoring system xCELLigence E-Plate 96 according to manufac-
turer's instructions (Roche diagnostics, New South Wales, Australia).
Cells were treated for 24 h after seeding and electrical impedanceFig. 1.Vinorelbine reduces placental cell viability and proliferation. (a) JEG3 and (b) HTR-8/SVn
dependently reduced JEG3 and HTR-8/SVneo viability, whilst combination methotrexate and
viability beyond that seen for methotrexate 100 μM methotrexate and in HTR-8/SVneo cell
viability beyond the combination methotrexate and geﬁtinib. Data are means ± SEM of six in
of (C) live, (D) apoptotic and (E) dead HTR-8/SVneo cells after indicated treatments. Vinorel
proportion of live cells relative to vehicle control (C). The proportion of apoptotic HTR-8
independent experiments in triplicate. (F) JEG3 and (G) HTR-8/SVneo proliferation measured
proliferation at all doses, 0.01–100 μM, within 10 h of treating. Methotrexate and combination
either cell type. Data are means ± SEM over time, of three independent experiments in tri
proliferative marker ki67 Ki67 (in green) after treating JEG3 and HTR-8/SVneo cells with 1 μ
staining represents DAPI nuclear staining. (I) First trimester placental explants treated for 4
control. Vinorelbine at 1 μM reduced secretion of β-hCG relative to control. Data are means ±
vs. vehicle control. †p b 0.05, ††p b 0.01, †††p b 0.001, ††††p b 0.0001 vs. methotrexate. #p b
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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cell growth. Measurements were recorded every 2 min for the ﬁrst 2 h
and every hour thereafter. Data were analyzed using RTCA software
(Roche).
2.3. Immunoﬂuorescence
After treating JEG3 andHTR-8/SVneo cells for 4 or 16 hwith vinorel-
bine, cells were ﬁxed in 4% paraformaldehyde for 30 min at room
temperature and permeabilized with triton X-100 (Sigma) for two mi-
nutes. Primary antibodies Ki67 (anti-rabbit; 1:1000; Abcam, Cambridge,
UK) or α-tubulin (anti-rabbit; 1:250; Millipore, Massachusetts, USA)
were diluted in 1%BSAwith 0.05% Triton X100 and applied at room tem-
perature overnight, followed by application of Alexaﬂuor488 ﬂuores-
cently conjugated secondary antibody (anti-rabbit; 1:1000; Invitrogen,
California, USA) for 1 h at room temperature. Cells were mounted
onto coverslips using mounting medium containing DAPI (Sigma). For
Ki67 staining images were captured using the EVOS-FL microscope. α-
tubulin staining was visualized using confocal microscopy outlined
below.
2.4. Confocal Microscopy
Fixed-cell confocal microscopy was performed using a Zeiss 880
laser scanning confocal microscope (Carl Zeiss, North Ryde, Australia).
α-Tubulin staining was excited using 488 nm laser and emission was
detected between 493 and 630 nmwith standard ﬂuorescence detector
(multi alkali PMT). Nuclear staining (DAPI) was excited with 405 nm
and emission was detected between 410 and 502 nm. The resulting
ﬂuorescence was imaged using 63x oil objective (NA 1.4) and acquired
digitallywith pixel size of 71nm in x and y. Imageswere taken as Z stack
with 400 nm interval and maximum intensity projection images were
created for 2 dimensional view. Figures were prepared using image J
software (NIH).
2.5. Flow Cytometry
To assess apoptosis and viability HTR-8/SVneo cells were labeled
with APC-annexin V (BD Pharmingen, New Jersey, USA) and Sytox
Blue (Life Technologies) in buffer containing 140 mM NaCl, 2.5 mM
CaCl2, and 10 mM HEPES in water, pH 7.4 after treating for 24 h. Flow
cytometry was performed with the use of a FACSVerse ﬂow cytometer
(BD Pharmingen), using the following excitation lasers and [band pass
detection ﬁlters]: APC-annexin V, 640 nm [660/10], Sytox Blue,
405 nm [448/45]. Compensation controls consisted of 1) unstained
cells, 2) APC-annexin V-labeled cells, and 3) Sytox Blue–labeled cells.
Flow cytometry data were analyzed with the use of FlowJo software
(v7.6.4, Tree Star, Inc., Ashland, Oregon) as follows. Plotswere displayed
with side scatter vs. forward scatter and gated to remove debris. Plots
were then displayed with Sytox Blue vs. APC-annexinV and separated
into quadrants. From this plot, the percentage of live (APC-annexin
Vlow/Sytox Bluelow), percentage of apoptotic (APC-annexin Vhigh/Sytox
Bluelow), and percentage of dead (Sytox Bluehigh) cellswere determined.eo cell viability measured via MTS assay after treating for 48 h treatment. Vinorelbine dose
geﬁtinib reduced HTR-8/SVneo viability. Vinorelbine at 1, 10 and 100 μM reduced JEG3
s at 100 μM. Vinorelbine at 100 μM in both trophoblast cell types signiﬁcantly reduced
dependent experiments in triplicate. (C–E) FACs cell sorting used to measure proportion
bine alone at 0.1 and 100 μM, and combination methotrexate and geﬁtinib reduced the
/SVneo cells increased with 100 μM vinorelbine (d). Data are means ± SEM of three
in real-time via xCELLigence. Vinorelbine signiﬁcantly reduced JEG3 and HTR-8/SVneo
methotrexate and geﬁtinib did not signiﬁcantly reduce proliferation at any time point in
plicate. (H) Representative images of immunoﬂuorescence showing a reduction in the
M vinorelbine (right hand panels) or equivalent control (left hand panels) for 4 h. Blue
8 h with methotrexate, combination geﬁtinib and methotrexate, vinorelbine or vehicle
SEM of ﬁve independent patient samples in triplicate. *p b 0.05, **p b 0.01, ***p b 0.001
0.05 vs. combination methotrexate and geﬁtinib. (For interpretation of the references to
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mined, after treating for 12 h, via DNA staining with propidium iodide
(Sigma). Cells were ﬁxed with 70% ethanol at −20 °C for 10 min
followed by staining with 50 μg/ml propidum iodide in PBS containing
1 mg/ml RNase A (Sigma) for 30 min. Flow cytometry for propidium
iodide was performed using 488 nm excitation and a 586/42 emission
ﬁlter. Data were displayed with side scatter vs. forward scatter and
gated to remove debris, and then as histograms for propidium iodide
intensity on a linear scale. The FlowJo CellCycle algorithmwith univari-
ate modeling was used to segment plots into G0/G1, S, and G2/M phases
of the cell cycle and to calculate the percentage of cells in each segment.
2.6. Ex Vivo Explants
First trimester placental tissue (10–11 + 4-wk gestation; n = 5)
were collected from consenting non-smoking women aged between
22 and 39 (mean: 31) yearswith a bodymass index (BMI) below31, un-
dergoing elective termination of pregnancy (Patient characteristics
Table. S1). Placental tissue was cut into small pieces and cultured in
DMEM (Life Technologies) media containing 10% fetal bovine serum
(FBS) at 37 °C in 2% O2 overnight. Explants were treated in triplicate
with vinorelbine; 0.1 and 1 μM, methotrexate; 100 μM, combination
methotrexate and geﬁtinib; 100 μM and 8 μM, respectively, or vehicle
control for 48 h. Tissue was weighed and culture supernatant collected
and stored at−20 °C for subsequent β-hCG assay.
Human fallopian tubes were collected at the time of hysterectomy
from non-smoking pre-menopausal women aged between 29 and 50
(mean 42) and BMI below 27 (Patient characteristics Table. S1). Tissue
was collected from the ampullary region of the fallopian tube, cut into
small pieces (2–3 mm) and cultured in RPMI (Life Technologies)
media containing 10% FBS at 37 °C in 5% O2 for 1 h. Explants were
then treated with increasing doses of vinorelbine (0.01, 0.1, 1 and 100
μM) or vehicle (PBS) control for 24 h (in triplicate). Explants were col-
lected and ﬁxed in RNAlater (Life technologies) for 48 h then subject
to western blot analysis. Human Ethics approval was obtained for this
study from the Mercy Health Human Research Ethics Committee
(R11/34) and Lothian Research Ethics Committee (study code LREC
08/S1101/1), and women gave informed written consent.
2.7. Western Blots
Cell and tissue lysates were prepared on ice in RIPA buffer (25 mM
tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS, 1% Pierce protease and phosphatase inhibitor),
followed by homogenization and then centrifugation at 20,000 g for
10 min at 4 °C to remove cell/tissue debris. SDS–polyacrylamide gel
electrophoresis (12 and 15%) with transfer onto PVDF membranes
was then performed with 15 μg (cells) or 20 μg (tissue) of protein
loaded per a sample. After blocking, membranes were incubated with
the primary antibody overnight at 4 °C. Dilutions were as follows:
anti-caspase-9 (Cell Signaling Technology, Massachusetts, USA),
1:1000; anti-caspase-3 (Cell Signaling Technology), 1:1000; anti-Bcl-2
(Cell Signaling Technology), 1:1000; anti-BAX (Abcam), 1:2000; anti-
BNIP3 (Sigma), 1:500; anti-ctyochrome-c (Abcam), 1:250; anti-
GAPDH, 1:5000. Anti-rabbit and anti-mouse secondary antibodies
were used at 1:2500 and 1:10,000, respectively. Targeted protein signal
was detected using an ECL detection kit (Amersham Bioscience) and
captured with ChemiDoc imaging system (BioRad). Images were ana-
lyzed using ImageJ software (version 1.50i).Fig. 2. Vinorelbine resolves placental mass in xenograft JEG3 model. JEG3 cells were subcutane
were treated (indicated by ↓) three times over twoweeks and tumor volumemeasured every s
5mg/kg, or equivalent PBS (n=8 per group). (A) Tumor volume (mm3) over time and (B) tum
dose dependently reduced tumor weight and (D) serum β-hCG levels at time of death. Data
2.5 mg/kg, methotrexate 2 mg/kg, methotrexate 2 mg/kg + geﬁtinib 25 mg/kg, or vehicle con
time of death compared to vehicle control, methotrexate and combination methotrexate
methotrexate. (H) Vinorelbine reduced serum hCG levels below all other treatment groups. Da
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All procedures were conducted under an animal care and use proto-
col, approved by the Austin Animal Ethics Committee at the Austin Hos-
pital. 1 × 106 JEG3 cells were subcutaneously injected into the right ﬂank
of 7–8 week old female SCID mice. Once palpable tumors had formed
micewere randomized into treatment groups and intravenous treatment
commenced via tail-vein injection, with three treatments over a two-
week period. Treatment groups consisted of (i) control, phosphate buffer
solution (PBS); (ii) vinorelbine 1.25 mg/kg; (iii) vinorelbine 2.5 mg/kg;
and (iv) vinorelbine 5 mg/kg. Following initial dose ﬁnding vinorelbine
treatments, a second group of mice were treated as follows; (i) control,
PBS + DMSO; (ii) methotrexate 2 mg/kg + DMSO; (iii) methotrexate
2 mg/kg + geﬁtinib 25 mg/kg and (iv) vinorelbine 2.5 mg/kg + PBS +
DMSO. In a third set of experiments, mice were treated with methotrex-
ate alone at the doses of 0.625, 1.25 and 2.5 mg/kg, or vehicle control on
days 6 and 9 post JEG3 inoculation. Mice weremonitored and tumor vol-
ume recorded every second day for up to eight days. At the conclusion all
mice were euthanized, blood collected via cardiac puncture and tumors
removed and weighed. Murine blood was centrifuged at 1500 g for
10 min, and serum stored at−20 °C for subsequent β-hCG assay. Note,
in accordance with animal ethics requirements, mice were humanely
killed once tumor volume rose above 1000 mm3.
2.9. Mice Fertility Studies
Female 6–8 week old Swiss mice were treated intravenously with
control PBS or vinorelbine 5mg/kg, three times over twoweeks. Follow-
ing the last treatment mice were rested for four weeks and subse-
quently mated with 6–8 week old Swiss male mice. At embryonic day
17.5 pregnant mice were euthanized; pups and placenta collected,
weighed, measured and ﬁxed in paraformaldehyde for 24 h. Maternal
blood was collected via cardiac puncture, centrifuged at 1500 ×g for
10min, and serum stored at−80 °C for subsequent Anti-MullerianHor-
mone (AMH) assay.
2.10. ELISA
Human β-hCG (Alpco, United States) concentration was measured
in cell culture medium taken from ﬁrst trimester placental explants
and serum collected from xenograft mice at the time death. Mouse
AMH (Elabscience, United States) concentrations were measured in
serum from mice where breeding post-vinorelbine treatment was
assessed. Samples were assessed in duplicate using commercial ELISA
kits according to manufacturer's instructions.
2.11. Statistics
The data were analyzed for statistical signiﬁcance using Graph Pad
Prism 6 (GraphPad Software, La Jolla, CA). Data was tested for normal
distribution and statistically analyzed as appropriate. When three or
more groups were compared a 1-way ANOVA (for parametric data) or
Kruskal-Wallis test (for non-parametric data) was used. Post-hoc anal-
ysis was carried out using either the Tukey (parametric) or Dunn's test
(non-parametric). When two groupswere analyzed, either an unpaired
t-test (parametric) or aMann-Whitney test (non-parametric)was used.
All data is expressed as mean ± SEM. P-values b 0.05 were considered
signiﬁcant.ously injected into female SCID mice, and treatment administered intravenously. All mice
econd day. (A-D)Mice treatedwith increasing doses of vinorelbine, 1.25mg/kg, 2.5 mg/kg,
or volume at time of death is reducedwith increasing doses of vinorelbine. (C) Vinorelbine
are means ± SEM. *p b 0.05, **p b 0.01, **p b 0.001. (e–h) Mice treated with vinorelbine
trol (n = 6 per group). (E) Vinorelbine alone reduced tumor volume over time and (F) at
and geﬁtinib. (G) Tumor weight is reduced by vinorelbine compared to control and
ta are means ± SEM.
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3.1. Vinorelbine is a Potent Inducer of Placental Cell Death
It is likely that methotrexate resolves ectopic pregnancies by induc-
ing cell death within the placenta. Thus, drugs that induce placental cell
death may be effective in medically treating ectopic pregnancies. We
initially screened eight chemotherapeutic agents, by MTS assay, for
their ability to reduce placental cell viability in vitro (Supplementary
Fig. 1). From this, we identiﬁed vinorelbine as a potent inhibitor of cell
viability. Given it is orally available, well tolerated and has potential to
be translated into the clinic, we selected vinorelbine for further study.
Vinorelbinewas administered to two human trophoblast (placental)
cell lines, JEG3 cells (models cytotrophoblast cells) and HTR-8/SVneo
cells (derived from human ﬁrst trimester placenta and have character-
istics of extravillous trophoblast cells) (Hannan et al., 2010; Mandl
et al., 2006). We treated JEG3 or HTR-8/SVneo cells with increasing
doses of vinorelbine (0.01-100 μM), as well as methotrexate (the only
medical treatment for ectopic pregnancy in the clinic), and combination
methotrexate and geﬁtinib (which is being evaluated in a large trial to
treat ectopic pregnancy). At 100 μM, methotrexate did not signiﬁcantly
reduce cell viability in either placental cell type (Fig. 1A, B). Combina-
tion methotrexate (at 100 μM) and geﬁtinib (at 8 μM) signiﬁcantly re-
duced cell viability in HTR-8/SVneo (Fig. 1B), but not JEG3 cells
(Fig. 1A). In contrast, vinorelbine signiﬁcantly reduced JEG3 and HTR-
8/svneo cell viability in a dose-dependent manner (Fig. 1A, B), down
to a concentration of 0.1 μMin JEG3 cells (1000 fold lower concentration
than the methotrexate dose) and 1 μM in HTR-8/svneo cells. Further-
more, vinorelbine at 100 μM also proved more efﬁcacious at inducing
placental cell death than combination methotrexate (also at 100 μM)
and geﬁtinib in both cell types.
We used ﬂow cytometry to further quantify the proportion of live,
apoptotic and dead HTR-8/SVneo cells after treatment. Reﬂecting the
ﬁndings of our end pointMTS assays, therewas no signiﬁcant difference
in the proportions of live, apoptotic or dead cells after treatment with
100 μMofmethotrexate (Fig. 1C–E). Combinationmethotrexate and ge-
ﬁtinib signiﬁcantly reduced the proportion of live cells (Fig. 1C), but not
the percentage of apoptotic or dead cells (Fig. 1D, E). In contrast, vino-
relbine reduced the proportion of live cells from 0.1 μM concentration
(1000 times lower than methotrexate) and increased apoptotic cells
at a dose of 100 μM (Fig. 1C, D). There were trends toward increased
proportions of dead cells with all drugs, though none were signiﬁcant
(Fig. 1E).
Next, we investigated the effects of vinorelbine on trophoblast pro-
liferation using the xCELLigence system (Ke et al., 2011). Unlike end-
point assays, this measures cell proliferation in real-time by recording
electrical impedance across wells. 12 h after treating with vinorelbine,
there was signiﬁcantly reduced cell proliferation in both JEG3 (Fig. 1F)
and HTR-8/SVneo (Fig. 1G) cells at all concentrations administered
(0.01-100 μM), compared to control. In contrast, neither methotrexate
alone (at 100 μM), nor combinationmethotrexate and geﬁtinib induced
a statistically signiﬁcant decrease in cell proliferation at any time point
after treatment (Fig. 1F, G). Of note, the administration of 0.01 μMvino-
relbine to HTR-8/SVneo cells was signiﬁcantly more efﬁcacious than
methotrexate at 100 μM (a concentration that is 10,000 times higher)
in reducing proliferation between 20 and 30 h after treatment
(Fig. 1G). Staining JEG3 and HTR-8/SVneo cells with the proliferation
marker Ki67. Fig. 1h showed a reduction in Ki67 staining (as seen byFig. 3.Vinorelbine causesmicrotubule condensation, arresting trophoblast cell cycle and leading
with vinorelbine or control equivalent for 16 h, stained with α-tubulin (green) and DAPI (blue
measured by intracellular staining of propidium iodide-A and FACs. (B) Representative histogra
and phase (purple). Treating with vinorelbine at (C) 1 μM and (d) 10 μMhalts cell cycle progre
relative proportion of cells in G0/G1, S and G2/M phases after vinorelbine treatment. Data are m
showing increased protein expression of apoptotic markers after treating JEG3 and HTR-8/S
SVneo (right) protein expression of Bcl-2, BAX, BNIP3 and caspase 9 and 3. Densitometric ana
of three independent experiments. *p b 0.05, **p b 0.01. (For interpretation of the references t
Please cite this article as: Hastie, R., et al., Vinorelbine Potently Induces Pla
for Ectopic Pregnancy, EBioMedicine (2017), https://doi.org/10.1016/j.ebigreen immunoﬂuorescence) after 4 h of vinorelbine treatment at 1
μM, compared to control treated cellswhere an abundance of cell prolif-
eration (Ki67 staining) is seen.
Together, our data thus far indicates that vinorelbine potently in-
duces trophoblast cell death and inhibits proliferation in vitro at doses
that are considerably lower than either methotrexate, or combination
methotrexate and geﬁtinib.
Using placental explants we next examined the potential of vinorel-
bine to reduce primary ﬁrst trimester placental tissue viability (Supple-
mentary Table 1 details clinical characteristics). After treatment, we
measured human chorionic gonadotrophin (hCG), a protein that is se-
creted into the circulation from the placenta and is amarker of placental
cell viability (serum hCG levels are serially measured in the clinic to
gauge the response to methotrexate when treating ectopic pregnancies
eithermedically or expectantly, where a fall below 5mIU indicates com-
plete resolution). Administeringmethotrexate at 100 μM±geﬁtinib did
not reduce hCG levels secreted into the culturemedia. In contrast, vino-
relbine at 1 μM, (a concentration that is 100 times lower than metho-
trexate) signiﬁcantly reduced hCG levels in the culture media (Fig. 1I).
3.2. Vinorelbine Potently Reduces Placental Xenografts In Vivo, and May be
More Efﬁcacious Than Methotrexate, or Combination Methotrexate and
Geﬁtinib
To further our in-vitro results we examined the potential of vinorel-
bine to regress placental cells in vivo. We used a model that we previ-
ously described where JEG3 cells are xenografted subcutaneously into
immune deﬁcient (SCID) female mice and placental tumors allowed
to form (Nilsson et al., 2013). Mice were then treated intravenously
(via tail vein) with 1.25, 2.5 or 5 mg/kg vinorelbine, or vehicle control
on days 6, 9 and 12 after xenograft inoculation. Compared to vehicle
controls, vinorelbine at all doses signiﬁcantly reduced xenograft volume
4 days after treatment (10 days after JEG3 inoculation) and each mea-
sured time point thereafter (12 and 14 days after inoculation)
(Fig. 2A, B). Furthermore, vinorelbine treatment caused a signiﬁcant,
dose dependent reduction in xenograft tumor weight (harvested at
the time of euthanasia) (Fig. 2C). There was a concordant dose depen-
dent reduction in serum hCG from blood taken at the time of euthana-
sia. Signiﬁcantly, we noted that at the top dose of vinorelbine
(5 mg/kg) 6 out of 8 mice had a resolution of the tumor to the extent
that no tumor could be found (Fig. 2C). Of these 6 mice, 5 had serum
hCG levels below the detectable range of the assay (Fig. 2D). This sug-
gests the possible complete absence of placental xenograft tumors in
5 mice.
Using the samemodel, we compared vinorelbine versusmethotrex-
ate alone, andmethotrexate with geﬁtinib. When compared against ve-
hicle control, methotrexate alone (at 2 mg/kg) or methotrexate with
geﬁtinib (at 25 mg/kg) did not reduce placental tumor volume at any
measured time point (Fig. 2e, f), tumor weight (Fig. 2g) or serum hCG
levels at the time of sacriﬁce (Fig. 2h). In a separate experiment, we
found methotrexate at 0.625, 1.25 and 2.5 mg/kg did not signiﬁcantly
decrease xenograft volume, weight or serum hCG (Supplementary
Fig. 2).
In contrast to methotrexate, vinorelbine at 2.5 mg/kg reduced pla-
cental tumor volume at every time point from 2 days after treatment,
(8 days after JEG3 inoculation) and each day thereafter (Fig. 2E, F).
Tumor weights (Fig. 2G) and serum hCG (Fig. 2H) were also signiﬁ-
cantly reduced with vinorelbine treatment. In direct statisticalto activation of apoptosis. (A)Microtubules of JEG3 andHTR-8/SVneo cells after treatment
). Scale bar = 10 μm. (B–E) HTR-8/SVneo cell cycle phases after treating with vinorelbine,
ms showing control treated cells with the proportions of cells in G0/G1 (green), S (yellow)
ssion at G2/M, reducing the proportion of cells in S and G0/G1 phases. (E) Quantiﬁcation of
eans ± SEM of three independent experiments in triplicate. (F–H) Western blot analysis
Vneo cells with vinorelbine. (F) Representative western blots of JEG3 (left) and HTR-8/
lysis of apoptotic markers in (G) JEG3 and (h) HTR-8/SVneo cells. Data are means ± SEM
o colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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7R. Hastie et al. / EBioMedicine xxx (2017) xxx–xxxcomparisons, vinorelbine was signiﬁcantly more effective at reducing
tumor volume than either methotrexate or combination methotrexate
and geﬁtinib from days 8 and 11 respectively (Fig. 2E, F), more effectivePlease cite this article as: Hastie, R., et al., Vinorelbine Potently Induces Pla
for Ectopic Pregnancy, EBioMedicine (2017), https://doi.org/10.1016/j.ebiin decreasing xenograft tumor weight compared to methotrexate
(Fig. 2G), and was associated with lower serum hCG compared to all
other treatments (Fig. 2H).cental Cell Death, Does Not Harm Fertility and is a Potential Treatment
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grafts in vivo, andmay be more efﬁcacious than either methotrexate, or
combination methotrexate and geﬁtinib.
3.3. Vinorelbine CausesMicrotubule Condensation, Blocks Mitosis and Acti-
vates Apoptosis Cascades in Placental Cells
Vinorelbine is thought to cause cell death by binding β-tubulin,
which depolarizes microtubulin, arrests cells in the metaphase to ana-
phase transition and ultimately leads to apoptosis of dividing cells
(Okouneva et al., 2003). Hence, we examined whether this occurred
in JEG3 and HTR-8/SVneo cells. After treating cells with vinorelbine,
we stained them for the presence of tubulin, using confocal microscopy
to visualize microtubulin. Administration of vinorelbine at 0.01 μM
showed a notable reduction in microtubule staining (green ﬂuores-
cence) in both cell types, compared to control. Additionally, the remain-
ing tubulin appeared disordered and condensed (Fig. 3A). Given this
condensation is thought to induce cell cycle arrest we next performed
ﬂow cytometry to measure cell cycle progression in HTR-8/SVneo cells
treated with vinorelbine. As expected, vinorelbine caused a signiﬁcant
G2/M block that coincided with a decrease in the proportion of cells in
G0/G1 and S phase (Fig. 3E). This is visualized by representative histo-
grams (Fig. 3B), where control treated cells show three distinct phases
G0/G1 (purple), S (yellow) and G2/M (green). However, histograms of
vinorelbine treated cells show a reduction in the percentage of cells in
G0/G1 and S phases and an increase G2/M, indicative of a G2/M mitosis
block (Fig. 3c, d). The reduction of cells in G0/G1 and the increase in
G2/M with vinorelbine treatment was statistically signiﬁcant (Fig. 3E).
In order to determine whether the cell cycle arrest caused by vino-
relbine activated apoptotic cascades in both trophoblast cell types, we
nextmeasured protein expression of apoptotic genes following vinorel-
bine treatment. In both cell types, vinorelbine treatment signiﬁcantly
reduced Bcl-2 expression (apoptosis inhibitor; Fig. 3F–G). In contrast,
we found vinorelbine treatment increased expression of the pro-
apoptotic markers BAX, BNIP3 and cleaved caspases 3 and 9 (Fig. 3F–
G). This suggests vinorelbine induces apoptosis in JEG3 and HTR-8/
SVneo cells and this may be the mechanism of placental cell death.
Collectively, our data indicates vinorelbine induces placental cell
death by condensingmicrotubules, leading to an expected G2/Mmitotic
block and the activation of apoptotic cascades.
3.4. Vinorelbine Does Not Up-Regulate pro-Apoptotic Molecules in Human
Fallopian Tubes and Does Not Affect Subsequent Fertility in Mice
Fertility preservation is major consideration for any potential treat-
ment for ectopic pregnancy as women diagnosed with this condition
are of reproductive age. It is possible vinorelbine could sparing the rela-
tively quiescent Fallopian tube cells. We exposed human Fallopian tube
explants obtained at hysterectomy from premenopausal women to
vinorelbine (0.01–100 μM) for 48 h (Table S2 details the clinical charac-
teristics). We then measured protein expression of the same apoptotic
markers that we have shown to be activated by vinorelbine in placental
cells. Vinorelbine did not increase expression of the pro-apoptotic mol-
ecules Bax, BNIP3, cytochrome c and caspases 3 and 9 (Fig. 4A, B) or re-
duce the expression of the apoptosis inhibitor Bcl-2 (Fig. 4A, B) in
human Fallopian tubes. Thus, vinorelbine does not appear to induce ap-
optosis in human Fallopian explants.While it is likely the presence of an
ectopic pregnancy itself may injure the Fallopian tube by causing scar-
ring (de Bennetot et al., 2012), our data provides reassurance that vino-
relbine does not seem to further induce cell death.
We next examined whether exposing mice to vinorelbine does af-
fects future fertility. Female mice of reproductive age were exposed to
three doses of vinorelbine at 5 mg/kg (the top dose used in our xeno-
graft model) or vehicle control. After a 4-week wash out period
(where the mice will have had 3–4 estrous (or menstrual) cycles)
mice were time mated and euthanized at embryonic day 17.5. TherePlease cite this article as: Hastie, R., et al., Vinorelbine Potently Induces Pla
for Ectopic Pregnancy, EBioMedicine (2017), https://doi.org/10.1016/j.ebiwere no differences between mice exposed to vinorelbine and controls
in the number of pups per litter (Fig. 4C), pup or placental weight
(Fig. 4D, E), crown to rump length (Fig. 4F), fetal placental ratio
(Fig. 4G) or gross fetal morphology (Fig. 4I). Maternal serum anti-
mullerian hormone (AMH) is measured clinically as an indicator of
ovarian reserve. Serum AMH concentrations in mice were no different
in the vinorelbine treated group, compared to controls (Fig. 4H) sug-
gesting vinorelbine does not adversely affect the follicle pool. Vinorel-
bine does not appear to adversely affect subsequent fertility, breeding
outcomes, or ovarian reserve.
4. Discussion
Here, we demonstrate that vinorelbine, an orally available andwell-
tolerated agent, has potential as a medical treatment for ectopic preg-
nancy. It appears to be highly active inducingplacental cell death at con-
centrations that are 100–1000 fold lower than methotrexate (the only
medical treatment used clinically), potently inhibits xenograft placental
growth, does not induce pro-apoptosis genes in human Fallopian tubes,
and does not impair subsequent fertility.
We ﬁrst identiﬁed vinorelbine through screening of several chemo-
therapeutic agents where vinorelbine proved to be highly potent in re-
ducing placental cell viability in both JEG3 and HTR-8/SVneo
trophoblast cells. Surprisingly, vinorelbine induced placental cell death
at doses that were 100 to 1000 times lower thanmethotrexate. Further-
more, vinorelbine reduced placental cell viability and proliferation be-
yond that of the combination of methotrexate (administered at the
same dose of vinorelbine alone in the same experiment) and geﬁtinib.
We next administered vinorelbine in a mouse model of ectopic preg-
nancy. In these in vivo experiments, the administration of vinorelbine
at the top dose, 5 mg/kg, completely resolved placental cell mass in 6
out of 8 mice, with no palpable tumors and undetectable serum hCG
concentrations (at the time of sacriﬁce) in 5 out of 8mice. In subsequent
experiments, directly comparing vinorelbine with methotrexate, and
combination methotrexate and geﬁtinib, vinorelbine alone (at
2.5 mg/kg) proved signiﬁcantly more efﬁcacious than either treatment
at resolving placental xenografts.
We have utilized a placental xenograft model, whichwas previously
used in the investigation of combination methotrexate and geﬁtinib for
ectopic pregnancy therapeutics (Nilsson et al., 2013). We note that this
in vivo model does not fully recapitulate an ectopic pregnancy and the
placental trophoblast tissue is not inoculated into the reproductive
tract. However, such an animal model of ectopic pregnancy has not
been described. Thus, we used an approach that has been widely used
to evaluate drugs in oncology. Nevertheless we believe our model still
provides highly informative data suggesting vinorelbine is able to suc-
cessfully target human trophoblast tissues in vivo, and is farmore efﬁca-
cious thanmethotrexate (the only drug used to treat ectopic pregnancy
in the clinic).
We note that in preclinical studies evaluating the use of vinorelbine
in malignancies, the dose typically administered in xenograft models is
20 mg/kg (Villena-Heinsen et al., 1998; Hill et al., 1999; Dal Bello et al.,
2015), four times higher than the highest dose used in our xenograft
studies. Thus, it is possible that trophoblast cells may be particularly
sensitive to vinorelbine in vivo, as well as in vitro. Furthermore, unlike
malignancies, ectopic pregnancy tissues will have far less genetic muta-
tions and resolve quicker than tumors, meaning acquired resistance to
treatment should not arise. Thus, if vinorelbine is evaluated in clinical
trials, dosing and dosing regimes could be substantially lower than
that used to treat cancer.
Additionally, vinorelbine oral formulations are routinely adminis-
tered in humans at 60 mg/m2 (Depierre et al., 2001) and intravenously
at 30 mg/m2 (Depierre et al., 1991; Fumoleau et al., 1993; Hirsh et al.,
2007). Extrapolating using FDA guidelines (Food Drug Administration,
2005) shows that administration of 2.5 mg/kg vinorelbine in a mouse
to be 7.4 mg/m2 human equivalent dose, approximately one quarter ofcental Cell Death, Does Not Harm Fertility and is a Potential Treatment
om.2018.01.041
Fig. 4. Vinorelbine does not up-regulate pro-apoptotic molecules in human Fallopian tubes and does not affect subsequent fertility in mice. (A–G) Human fallopian tubes were collected
frompremenopausalwomen at the time of hysterectomy and treatedwith increasing doses of vinorelbine (0.01, 0.1, 1, 100 μM)or equivalent PBS for 24 h. (A) Representativewestern blot
analysis performed for apoptoticmarkers Bcl-2, BAX, BNIP3, cytochrome c and caspase 9 and 3. (B) Densitometric analysiswas performed onn=8 samples for each apoptoticmarker. The
pro-apoptotic marker Bax was reduced with 0.01 μMvinorelbine. (C-I) Female swiss mice intravenously treated with vinorelbine 5 mg/kg or equivalent PBS, three times over twoweeks.
Four weeks post ﬁnal treatment, mice were mated and then culled at embryonic day 17.5, pups, placenta andmaternal blood were collected. (C) Litter size, (d) pup weight, (E) placental
weight, (F) crown to rump length, (G) fetal placental ratio, (H)maternal serum levels of anti-mullerian hormone and (i) gross fetal morphology did not differ between control and treated
groups (n= 7 per a group, no difference in vinorelbine or control treated by un-paired t-test). Data are means ± SEM. *p b 0.05 by 1-way ANOVA with Tukeys Test, comparing doses of
vinorelbine treatment with vehicle control treatment.
9R. Hastie et al. / EBioMedicine xxx (2017) xxx–xxxthe average intravenous dose of 30 mg/m2. Thus, the doses we exam-
ined in our in vivo model were directly clinically relevant. Furthermore,
with over 390 registered phase I to IV clinical trials assessing vinorelbine
as a single agent or in combination treatment, robust information exists
reporting the safety and tolerability of this chemotherapeutic (Marty
et al., 2001; Gebbia and Puozzo, 2005; Depierre et al., 2001). Although
neutropenia is the dose limiting toxicity for this chemotherapeutic,
this is often only seen with prolonged treatment (Gebbia and Puozzo,
2005). Of other toxicities reported, including diarrhea, nausea and
vomiting, these are seldom severe and usually respond to treatment
(Depierre et al., 2001; Gregory and Smith, 2000). Additionally, metro-
nomic vinorelbine (dense, nonbreak, low dose administration) is safely
used and well tolerated, with some instances of treatment continuing
for over 3 years without overt toxicity (Briasoulis et al., 2009;Please cite this article as: Hastie, R., et al., Vinorelbine Potently Induces Pla
for Ectopic Pregnancy, EBioMedicine (2017), https://doi.org/10.1016/j.ebiCamerini et al., 2015; Bilir et al., 2017). Furthermore, one report of 62
patients treated with metronomic vinorelbine (20–70 mg thrice
weekly) reported non-hematological toxicities to be practically absent,
describing vomiting and nausea as negligible (Briasoulis et al., 2009).
Therefore, we believe if vinorelbine is translated into clinical use for ec-
topic pregnancy, due to the short treatment period and potential low
dosing, toxicities related to vinorelbine may be mitigated.
Ongoing fertility is likely to be an important consideration for
women diagnosed with an ectopic pregnancy when weighing up their
management options. To address this potential concern, we exposed
mice to the top dose of vinorelbine, which was highly effective in
regressing the placental xenografts (5mg/kg), and assessed subsequent
fertility. Reassuringly, vinorelbine did not appear to affect litter size, the
pups, or placental weight. Levels of serum anti-mullerian hormonecental Cell Death, Does Not Harm Fertility and is a Potential Treatment
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though longer-term fertility outcomes where not assessed here, we
are reassured by epidemiological reports of successful pregnancy out-
comes following vinca-alkaloid treatment in women of reproductive
age (Hodgson et al., 2007; Gershenson, 1988). Although reporting is
limited on fertility outcomes following vinorelbine treatment as a
drug class vinca-alkaloids are considered low risk for inducing gonadal
toxicity (Sonmezer and Oktay, 2004; Shamberger et al., 1981). In sup-
port of our preclinical data on fertility, we note that reassuring human
fertility data exists for vincristine, another vinca-alkaloid. In women
with choriocarcinoma, treated with a chemotherapy regimen including
vincristine but chose to retain their uterus: all resumedmenses (100%),
had successful pregnancies and did not appear to result in early meno-
pause (Wong et al., 2014). In another study, there was no increase in
chemotherapy-induced amenorrhoea (cessation of periods) among
women treatedwith high dose vinorelbine (Zhou et al., 2010). Rat stud-
ies performed by others have shown vinorelbine is embryotoxic in low
doses, however rats exposed to vinorelbine remain fertile (Pierre Fabre
Mèdicament Production, 2002).
Our data has strong potential clinical implications. With only
30% of diagnosed ectopic pregnancies estimated to be eligible for
methotrexate treatment (Jurkovic and Wilkinson, 2011) there is
currently a large treatment bias towards surgery for this condition.
It is therefore plausible that vinorelbine, which has proved more
efﬁcacious at lower doses than methotrexate in our pre-clinical
work, could successfully treat larger ectopic pregnancies and ex-
pand the number of ectopic pregnancies that can be treated medi-
cally. Together our data here provide strong evidence to justify
clinical trials to determine the efﬁcacy of oral vinorelbine to treat
ectopic pregnancy.
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